Reuters -- Celgene Corp said on Wednesday that pooled results from company-sponsored studies of its Amrubicin drug in relapsed small cell lung cancer showed it might be less toxic to the heart than traditional drugs in the same class.
Reuters -- Celgene Corp said on Wednesday that pooled results from company-sponsored studies of its Amrubicin drug in relapsed small cell lung cancer showed it might be less toxic to the heart than traditional drugs in the same class.
